NCT03123588 2021-11-19
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Incyte Corporation
Phase 2 Terminated
Incyte Corporation
CTI BioPharma
Hamad Medical Corporation
Sierra Oncology LLC - a GSK company
Exelixis